Skip to main content

Table 4 Changes in HbA1c in each age group

From: Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study

 

<65 years

65–74 years

≥75 years

 

Baseline

24 months

P value

Baseline

24 months

P value

Baseline

24 months

P value

HbA1c (%) of patients with 2-year data (n = 831)

8.1 ± 1.2

7.3 ± 0.9

<0.05

7.6 ± 0.9

7.0 ± 0.7

<0.05

7.7 ± 0.9

7.1 ± 1.1

<0.05

HbA1c (%) of patients receiving sitagliptin plus SU (n = 529)

8.2 ± 1.3

7.3 ± 0.9

<0.05

7.6 ± 0.9

7.0 ± 0.8

<0.05

7.8 ± 0.9

7.1 ± 0.8

<0.05

  1. HbA1c, hemoglobin A1c, SU, sulfonylurea
  2. Data are presented as the mean ± standard deviation unless otherwise indicated